About the genomic cancer medicine program

About the genomic cancer medicine program

Prof David Thomas
Prof David Thomas

About genomic medicine

Genomic medicine is the future for all cancer treatment, but will have its greatest impact for ‘rare’, high-mortality cancers.

Professor David Thomas is an oncologist and Head of Cancer Research at Garvan and Director of the Kinghorn Cancer Centre (a joint facility of Garvan and St Vincent’s Hospital, Sydney).

‘There is an unmet clinical need in the population with high-mortality and advanced cancers, for whom few therapeutic options exist and who have historically been neglected by the drug development process.

Read more

More about rare cancers

Cancer is usually considered a disease of older people, with mortality rates increasing with age for most cancers. One of the key characteristics of rarer cancers, however, is that these cancers place a great burden on children and young families. In every age group (Baby Boomers, Gen X, Gen Y, and even children) ‘rare’, high-mortality cancers are the most common cause of disease-related death in Australia.

Reasons for the high mortality rates include:

  • difficulty in diagnosis (as they are seen less often)
  • standard treatments are often less effective
  • there is limited access to new therapies.

 

Read more